Fogorvosi szemle, 2019 (112. évfolyam, 1-4. szám)

2019-09-01 / 3. szám

FOGORVOSI SZEMLE

112. évf. 3. sz. 2019.n

92

8. DAL PRA KJ, LEMOS CA, OKAMOTO R, SOUBHIA AM, PELLIZZER EP: Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. International journal of oral and maxillofacial surgery. 2017; 46 (2): 151–156.

9. DAMM DD, JONES DM: Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. General den

tistry. 2013; 61 (5): 33–38.

10. DEBAZ C, HAHN J, LANG L, PALOMO L: Dental Implant Supported Restorations Improve Quality of Life in Osteoporotic Women. Int J Dent. 2015; 2015: 451923.

11. DELMAS PD, EASTELL R, GARNERO P, SEIBEL MJ, STEPAN J: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2000; 11 Suppl 6: s2–17.

12. GARNERO P, BOREL O, DELMAS PD: Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clinical chemistry

. 2001; 47 (4): 694–702.

13. GELAZIUS R, POSKEVICIUS L, SAKAVICIUS D, GRIMUTA V, JUODZBALYS G: Dental Implant Placement in Patients on Bisphosphonate Therapy: a Systematic Review. J Oral Maxillofac Res.

2018; 9 (3): e2.

14. GIOVANNACCI I, MELETI M, MANFREDI M, MORTELLARO C, GRECO LUCCHINA A, BONANINI M, et al.: Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? The Journal of cran

iofacial surgery. 2016; 27 (3): 697–701.

15. GOSS A, BARTOLD M, SAMBROOK P, HAWKER P: The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg. 2010; 68 (2): 337–343.

16. GYIRES K FZ: Farmakológia alapjai. Medicina,

2011.

17. JACOBSEN C, METZLER P, ROSSLE M, OBWEGESER J, ZEMANN W, GRATZ KW: Osteopathology induced by bisphosphonates and dental im

plants: clinical observations. Clinical oral investigations

. 2013; 17 (1): 167–175.

18. JOÓB FA, KÖRMÖCZI K, NÉMETH ZS, BOGDÁN S: Társszakmák szerepe a szájsebészeti beavatkozások során, avagy miért tartozik szorosan össze az arc-, állcsont-, szájsebészet és a dento-alveolaris szájsebészet. Magyar Fogorvos: A magyar orvosi kamara fogorvosi tagozatának lapja. 2015; 24: (4) 190–194.

19. KENNETH E FLEISHER RK, SVEN O: Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ) – a Guide to Research. Thieme 1st edition. 2016 september 64. 29–35.

20. KHAN AA, MORRISON A, HANLEY DA, FELSENBERG D, MCCAULEY LK, O’RYAN F, et al.: Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Jour

nal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2015; 30 (1): 3–23.

21. KHOURY F, HIDAJAT H: Extensive Autogenous Bone Augmentation and Implantation in Patients Under Bisphosphonate Treatment: A 15-Case Series. The International journal of periodontics & re

storative dentistry. 2016; 36 (1): 9–18.

22. KIM JW, KONG KA, KIM SJ, CHOI SK, CHA IH, KIM MR: Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone

. 2013; 57 (1): 201–205.

23. KOKA S, BABU NM, NORELL A: Survival of dental implants in postmenopausal bisphosphonate users. Journal of prosthodontic re

search. 2010; 54 (3): 108–111.

24. KWON TG, LEE CO, PARK JW, CHOI SY, RIJAL G, SHIN HI: Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clinical oral implants research

. 2014; 25 (5): 632–640.

25. KWON YD, OHE JY, KIM DY, CHUNG DJ, PARK YD: Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clinical oral implants research

. 2011; 22 (1): 100–105.

26. LAZAROVICI TS, YAHALOM R, TAICHER S, SCHWARTZ-ARAD D, PELEG O, YAROM N: Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg

. 2010; 68 (4): 790–796.

27. LEE JJ, CHENG SJ, WANG JJ, CHIANG CP, CHANG HH, CHEN HM, et al.: Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study. Head & neck. 2013; 35 (12): 1787–1795.

28. LO JC, O’RYAN FS, GORDON NP, YANG J, HUI RL, MARTIN D, et al.: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg

. 2010; 68 (2): 243–253.

29. LOMBARD T, NEIRINCKX V, ROGISTER B, GILON Y, WISLET S: Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. Stem cells international. 2016; 2016: 8768162.

30. MADRID C, SANZ M: What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clinical oral implants research

. 2009; 20 Suppl 4: 87–95.

31. MARX RE, CILLO JE, JR., ULLOA JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg

. 2007; 65 (12): 2397–2410.

32. MEMON S, WELTMAN RL, KATANCIK JA: Oral bisphosphonates: early endosseous dental implant success and crestal bone changes. A retrospective study. The International journal of oral & maxillo

facial implants. 2012; 27 (5): 1216–1222.

33. MENDES V, DOS SANTOS GO, CALASANS-MAIA MD, GRANJEIRO JM, MORASCHINI V: Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence. In

ternational journal of oral and maxillofacial surgery. 2018.

34. nagy r sk, szűcs a, ruszin t, Joób-Fá: A rheumatoid arthritis hatása a szájsebészeti és implantológiai ellátásban a szakirodalom alapján. Fogorvosi szemle

. 2017; 110 (1): 3–6.

35. POGREL MA, RUGGIERO SL: Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series. International journal of oral and maxillofacial surgery

. 2018; 47 (2): 220–222.

36. QI WX, TANG LN, HE AN, YAO Y, SHEN Z: Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. International journal of clinical oncology. 2014; 19 (2): 403–410.

37. RISTOW O, PAUTKE C: Auto-fluorescence of the bone and its use for delineation of bone necrosis. International journal of oral and maxillofacial surgery. 2014; 43 (11): 1391–1393.

38. RUGGIERO SL, DODSON TB, ASSAEL LA, LANDESBERG R, MARX RE, MEHROTRA B, et al.: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg

. 2009; 67 (5 Suppl): 2–12.

39. RUGGIERO SL, DODSON TB, FANTASIA J, GOODDAY R, AGHALOO T, MEHROTRA B, et al.: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg

. 2014; 72 (10): 1938–1956.

40. SAAD F, BROWN JE, VAN POZNAK C, IBRAHIM T, STEMMER SM, STOPECK AT, et al.: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. Annals of oncology: official journal of the European Society for Medical Oncology. 2012; 23 (5): 1341–1347.

41. SCAGLIOTTI GV, HIRSH V, SIENA S, HENRY DH, WOLL PJ, MANEGOLD C, et al.: Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. Jour

nal of thoracic oncology: official publication of the International